Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized study of two nucleos(t)ide analogue strategies to prevent hepatitis B recurrence after liver transplantation
ChiCTR-PRC-10001092Phase 4Completed
- Sponsor
- Tianjin First Central Hospital
- Start
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of hepatitis B immune globulin in hepatitis B (HBV) (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoints: HBV-DNA, HBsAg and 10 more. Started Jun 2010; status: completed.
02
Drugs
hepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-PRC-10001092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-10001092.